Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
More News related to ONXX
- Notable Mergers and Acquisitions of the Day 11/16: CSCO, MOT, TTMI, ONXX
- Onyx Pharmaceuticals (ONXX) Completes Acquisition of Proteolix
- Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
- Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
More News related to Press Releases
- Pinnacle Gas (PINN) to Form Special Committee to Review Possible Proposals, Including Asset Divestitures, Equity Offerings
- Bunge (BG) To Acquire Brazilian Sugarcane Company Moema in an Estimated $1.35B Transaction
- Net 1 UEPS (UEPS) Acquires MediKredit Integrated in $10M Transaction
- Google (GOOG) Acquires San Mateo Startup Teracent
- Green Mountain Coffee Roasters Confirms $30/Share Cash Bid for Diedrich Coffee Following Raised Peet's Bid (GMCR, DDRX, PEET)
EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, at 9:30 a.m. Mountain Time (8:30 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through December 11, 2009.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.
SOURCE Onyx Pharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
